Synthesizing and investigating novel synthetic cannabidiol congeners for enhanced clinical utility

Title:

Synthetic Cannabidiol Congeners for Enhanced Clinical Utility

Tech ID:

2023-001

Status:

Active

Category:

Pharmaceuticals and Synthetic Cannabinoid Research

Executive Statement:

Innovative synthetic cannabidiol compounds designed to improve treatment options for seizures, anxiety, and inflammatory conditions.

Description:

This technology involves the synthesis and investigation of novel synthetic cannabidiol congeners aimed at providing enhanced therapeutic benefits. These compounds are developed through advanced synthetic methods and supported by preclinical evidence demonstrating their potential efficacy across multiple clinical indications such as seizures, epilepsy, anxiety, and inflammatory diseases.

Key Advantages:

• Enhanced potency and specificity compared to natural cannabidiol
• Improved clinical efficacy for neurological and inflammatory conditions
• Scalable and controlled synthetic production methods
• Potential for tailored therapeutic profiles targeting multiple indications
• Reduced variability and improved safety profiles versus plant-derived cannabinoids

Problems Solved:

• Limitations in efficacy and bioavailability of natural cannabidiol
• Inconsistent quality and supply issues with plant-based cannabis extracts
• Need for targeted therapies addressing seizures, anxiety, and inflammation
• Side effects and drug interactions associated with existing treatments

Market Opportunity:

• Treatment of epilepsy and seizure disorders
• Management of anxiety and related mental health conditions
• Therapies for inflammatory diseases and chronic pain
• Pharmaceutical development of cannabinoid-based drugs
• Clinical research for novel neurologic and psychiatric therapies

Inventors:

• Rochelle Hines 
• Dustin Hines 
• William Maio